Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A Medical Economic Perspective

American Journal of Kidney Diseases

Volumn 50, Issue 3, 2007, Pages 362-365

  Cohen, Joshua T ^a   Neumann, Peter J ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

CONFIDENCE INTERVAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DOSE KIDNEY FUNCTION RELATION; DRUG COST; EDITORIAL; HEALTH CARE FACILITY; HEALTH CARE POLICY; HEALTH ECONOMICS; HEMATOCRIT; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; ORGANIZATION AND MANAGEMENT; PATIENT CARE; PROFIT; REIMBURSEMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE;

AMBULATORY CARE FACILITIES; ANEMIA; ECONOMICS, MEDICAL; EPOETIN ALFA; HEMATINICS; HUMANS; OWNERSHIP; RENAL DIALYSIS;

EID: 34548027310     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.07.009     Document Type: Editorial

References (21)

1. Thamer M., Zhang Y., Kaufman J., Cotter D., Dong F., and Hernan M.A. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA 297 (2007) 1667-1674
2. Szczech L.A., Klassen P.S., Chua B., et al. Associations between CMS's Clinical Performance Measures project benchmarks, profit structure, and mortality in dialysis units. Kidney Int 69 (2006) 2094-2100
3. Collins A.J., Ebben J.P., and Gilbertson D.T. EPO adjustments in patients with elevated hemoglobin levels: Provider practice patterns compared with recommended practice guidelines. Am J Kidney Dis 49 (2007) 135-142
4. US Renal Data System. USRDS 2006 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States (2006), National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disorders
5. Coyne D.W. Use of epoetin in chronic renal failure. JAMA 297 (2007) 1713-1716
6. Devereaux P.J., Schunemann H.J., Ravindran N., et al. Comparison of mortality between private for-profit and private not-for-profit hemodialysis centers: A systematic review and meta-analysis. JAMA 288 (2002) 2449-2457
7. Garg P.P., Frick K.D., Diener-West M., and Powe N.R. Effect of the ownership of dialysis facilities on patients' survival and referral for transplantation. N Engl J Med 341 (1999) 1653-1660
8. Woolhandler S., and Himmelstein D.U. The high costs of for-profit care. CMAJ 170 (2007) 1814-1815
9. Carlson M.D., Gallo W.T., and Bradley E.H. Ownership status and patterns of care in hospice: Results from the National Home and Hospice Care Survey. Med Care 42 (2004) 432-438
10. Devereaux P.J., Choi P.T., Lacchetti C., et al. A systematic review and meta-analysis of studies comparing mortality rates of private for-profit and private not-for-profit hospitals. CMAJ 166 (2002) 1399-1406
11. Harrington C., Woolhandler S., Mullan J., Carrillo H., and Himmelstein D.U. Does investor ownership of nursing homes compromise the quality of care?. Am J Public Health 91 (2001) 1452-1455
12. Cotter D., Thamer M., Narasimhan K., et al. Translating epoetin research into practice: The role of government and the use of scientific evidence. Health Aff (Millwood) 25 (2006) 1249-1259
13. Centers for Medicare and Medicaid Services. CMS Manual System. Pub 100-04 Medicare Claims Processing. Transmittal 1043. Change Request 5251. 8-25-2006. Available at: http://www.cms.hhs.gov/Transmittals/Downloads/R1043CP.pdf. Accessed June 1, 2007
14. de L.G., Powe N.R., Griffiths R.I., et al. The relationship of provider organizational status and erythropoietin dosing in end stage renal disease patients. Med Care 32 (1994) 130-140
15. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Available at: http://www.kidney.org/professionals/KDOQI/guidelines_anemia/index.htm. Accessed January 18, 2007
16. Zhang Y., Thamer M., Stefanik K., Kaufman J., and Cotter D.J. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44 (2004) 866-876
17. Strippoli G.F., Navaneethan S.D., and Craig J.C. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. Cochrane Database Syst Rev (2006) CD003967
18. Tonelli M., Winkelmayer W.C., Jindal K.K., Owen W.F., and Manns B.J. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int 64 (2003) 295-304
19. Kalantar-Zadeh K., McAllister C.J., Lehn R.S., Lee G.H., Nissenson A.R., and Kopple J.D. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 42 (2003) 761-773
20. Blake G.J., Ridker P.M., and Kuntz K.M. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. Am J Med 114 (2003) 485-494
21. McMahon P.M., Araki S.S., Sandberg E.A., Neumann P.J., and Gazelle G.S. Cost-effectiveness of PET in the diagnosis of Alzheimer disease. Radiology 228 (2003) 515-522